Chris Schott
Stock Analyst at JP Morgan
(0.4)
# 2079
Out of 5,218 analysts
124
Total ratings
47.89%
Success rate
5.07%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
AbbVie | Maintains: Overweight | 210 200 | 173.5 | 15.27% | 2 | Nov 13, 2024 | |
Gilead Sciences | Maintains: Overweight | 100 105 | 91.85 | 14.32% | 3 | Nov 7, 2024 | |
Biogen | Maintains: Neutral | 220 210 | 150.04 | 39.96% | 3 | Nov 4, 2024 | |
Regeneron Pharmaceut... | Maintains: Overweight | 1200 1150 | 730.7 | 57.38% | 5 | Oct 24, 2024 | |
Teva Pharmaceutical ... | Maintains: Neutral | 16 18 | 16.48 | 9.22% | 9 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 630 575 | 432.18 | 33.05% | 7 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 225 230 | 178.34 | 28.97% | 2 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 1050 1100 | 789.07 | 39.4% | 19 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 18 20 | 15.32 | 30.55% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 9 | 7.83 | 14.94% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 48 41 | 27.42 | 49.53% | 8 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 45 42 | 24.84 | 69.08% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 270 | 270.45 | -0.17% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 36 34 | 25.59 | 32.86% | 7 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 120 125 | 102.09 | 22.44% | 6 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 14 | 12.63 | 10.85% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 11 | 1.61 | 583.23% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 24 20 | 12.12 | 65.02% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 175 150 | n/a | n/a | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 74 78 | 55.73 | 39.96% | 4 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 110 | n/a | n/a | 1 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 700 950 | 6.02 | 15680.73% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 5 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 9 | n/a | n/a | 6 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 45 50 | 19.82 | 152.27% | 3 | Nov 2, 2018 |